Searched for
SUN RANBAXY DEAL
Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Ranbaxy ends last trading day on bright note; surges over 5%Sun Pharmaceutical Industries also rose by 5.51 per cent to settle at Rs 1,078.55. The stock was the top gainer among the 30-Sensex scrips.
- Sun-Ranbaxy $4 billion merger completedSun Pharmaceutical Industries today said merger of Ranbaxy with itself has been 'consummated' following receipt of requisite approvals.
- Sun Pharma gets RBI nod for transfer of Ranbaxy's overseas investmentsThe central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, t...
- Sun-Ranbaxy $4 billion deal: US anti-trust regulator FTC passes final orderFTC has passed its final order settling charges that Sun Pharma's $4 billion deal to acquire Ranbaxy Laboratories could result in unfair bu...
- Sun-Ranbaxy deal gets CCI nod, with divestment riderAsked by CCI to divest seven products, drug makers Sun Pharmaceutical and Ranbaxy today said they will comply with the conditions put forth...
- Sun Pharma to firm up steps to boost Ranbaxy drug salesThe drug maker also plans to draw up detailed cross-selling plans for each state, according to industry consultants familiar with the matte...
- Sun-Ranbaxy deal: CCI raises concerns about market concentration of moleculesThe CCI today said the major issue is whether the Sun-Ranbaxy deal would result in high market concentration of certain molecules.
- Sun-Ranbaxy deal, the first merger deal to get showcause notice, to be an acid test for CCISince 2011, CCI has cleared some 165 deals, including 46 in 2013 and more than 30 so far this year, according to data available on its webs...
- Sun Pharma denies unit's role in Ranbaxy share run-up before dealSun Pharma said it had "no access to non-public information of Ranbaxy" when its unit Silverstreet bought shares in Ranbaxy.
- Andhra Pradesh High Court puts on hold Sun-Ranbaxy deal till insider trade verdictShares of Ranbaxy, which is majority-owned by Japan’s Daiichi-Sankyo, saw an unusual increase in price and turnover during six trading days...
- Sun Pharma denies insider trading charges in Ranbaxy dealSun Pharma denied insider trading charges against Silverstreet Developers- its wholly owned arm - in the $4 bn acquisition deal of Ranbaxy ...
- Buy Sun Pharma shares through RanbaxyAn investor who is really confident that the deal will go through can buy Ranbaxy shares and pocket the difference when the merger is compl...
- Sun-Ranbaxy deal: How India’s biggest pharma merger is also the quickest to get done, stitched up in just 2 monthsSun and their Japanese counterparts met for the first time as recently as the third week of March. A final agreement was in place by the en...
- Market gives a thumbs-up to Ranbaxy deal; Sun Pharma and Daiichi Sankyo gainShares of Sun Pharma surged 2.68 per cent or Rs 15.35 to close at Rs 587.25 as the all-share deal’s swap ratio is seen to favour investors ...
- Sun Pharma-Ranbaxy deal: Daichi Sankyo failed to harness the complexities of a strong generic business, says Malvinder SinghThe Sun-Ranbaxy combined entity will unlock the true potential of the Gurgaon based company, says former Ranbaxy owner Malvinder Singh.
- Sun Pharma to buy Ranbaxy in $3.2 bn deal: HighlightsSun Pharmaceutical Industries said that it will buy generic drug maker Ranbaxy Laboratories, has hit regulatory snags in its key US market ...
Load More
